Literature DB >> 9372255

Adenoid cystic carcinoma of the head and neck.

A S Jones1, J W Hamilton, H Rowley, D Husband, T R Helliwell.   

Abstract

Adenoid cystic carcinoma has a long natural history but frequently proves fatal. The present study describes 108 patients with an adenoid cystic carcinoma of the head and neck seen over a 30-year period. Analysis of the data utilized both univariate and multivariate methods. Forty per cent of patients had tumours arising from the oral cavity and half of these were in the hard palate; 29% occurred in the major salivary glands; 41% of tumours were locally advanced at presentation and 11% had lymph node metastases at this time. The histological pattern was solid in 25%, cribriform in 40% and tubular in 20%. In addition, 15% of patients had a polymorphous low-grade adenocarcinoma and these were analysed separately. Primary site recurrence was more common in the presence of locally advanced tumours at presentation (T3-4) (P = 0.0093). Only six patients had surgery with adjuvant radiotherapy. Six patients had no curative treatment, 21 had primary radiotherapy, 39 had local excision and 42 radical excision. The actuarial primary site recurrence rate was 100% at 30 years. The neck node recurrence rate was 23% at 15 years. Tumour specific survival was 40% at 20 years. Solid histology had a worse prognosis than other histological types (P = 0.0429) but those patients with polymorphous low-grade adenocarcinomas fared very well. Patients with tumours of the hard palate fared better than those patients with tumours at other sites (P = 0.0301). Early disease at the primary site (T1-2) was a good prognostic sign (P = 0.0013). Patients with neck node metastases at presentation tended to do badly (P = 0.009).

Entities:  

Mesh:

Year:  1997        PMID: 9372255     DOI: 10.1046/j.1365-2273.1997.00041.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  20 in total

1.  Predictors of Outcome in Adenoid Cystic Carcinoma of Salivary Glands: A Clinicopathologic Study With Correlation Between MYB Fusion and Protein Expression.

Authors:  Bin Xu; Esther Drill; Allen Ho; Alan Ho; Lara Dunn; Carlos Nicolas Prieto-Granada; Timothy Chan; Ian Ganly; Ronald Ghossein; Nora Katabi
Journal:  Am J Surg Pathol       Date:  2017-10       Impact factor: 6.394

2.  Clinicopathological review and survival characteristics of adenoid cystic carcinoma.

Authors:  Fariba Binesh; Ali Akhavan; Omid Masumi; Abbas Mirvakili; Nasim Behniafard
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2014-08-05

3.  Distant Metastases in Patients with Carcinoma of the Major Salivary Glands.

Authors:  Safina Ali; Robert Bryant; Frank L Palmer; Monica DiLorenzo; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2015-03-06       Impact factor: 5.344

Review 4.  Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review.

Authors:  Carlos Suárez; Leon Barnes; Carl E Silver; Juan P Rodrigo; Jatin P Shah; Asterios Triantafyllou; Alessandra Rinaldo; Antonio Cardesa; Karen T Pitman; Luiz P Kowalski; K Thomas Robbins; Henrik Hellquist; Jesus E Medina; Remco de Bree; Robert P Takes; Andrés Coca-Pelaz; Patrick J Bradley; Douglas R Gnepp; Afshin Teymoortash; Primož Strojan; William M Mendenhall; Jean Anderson Eloy; Justin A Bishop; Kenneth O Devaney; Lester D R Thompson; Marc Hamoir; Pieter J Slootweg; Vincent Vander Poorten; Michelle D Williams; Bruce M Wenig; Alena Skálová; Alfio Ferlito
Journal:  Auris Nasus Larynx       Date:  2016-03-24       Impact factor: 1.863

5.  MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.

Authors:  Eleni M Rettig; Marietta Tan; Shizhang Ling; Raluca Yonescu; Justin A Bishop; Carole Fakhry; Patrick K Ha
Journal:  Laryngoscope       Date:  2015-05-11       Impact factor: 3.325

6.  A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).

Authors:  Athanassios Argiris; Musie Ghebremichael; Barbara Burtness; Rita S Axelrod; Ronald C Deconti; Arlene A Forastiere
Journal:  Cancer       Date:  2011-01-18       Impact factor: 6.860

7.  Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel.

Authors:  Naoki Fukuda; Yu Fujiwara; Xiaofei Wang; Akihiro Ohmoto; Tetsuya Urasaki; Naomi Hayashi; Yasuyoshi Sato; Kenji Nakano; Mayu Yunokawa; Makiko Ono; Junichi Tomomatsu; Shunji Takahashi
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-11-21       Impact factor: 2.503

Review 8.  Paranasal sinus cancer: caveats and controversies.

Authors:  John Waldron; Ian Witterick
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

9.  Risk factors for survival and distant metastasis in 125 patients with head and neck adenoid cystic carcinoma undergoing primary surgery.

Authors:  In Seong Jeong; Jong-Lyel Roh; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-06       Impact factor: 4.553

10.  Adenoid cystic carcinoma of the parotid gland: Anastamosis of the facial nerve with the great auricular nerve after radical parotidectomy.

Authors:  Osman Bahadir; Murat Livaoglu; Ahmet Ural
Journal:  Indian J Plast Surg       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.